№43Brief2026-07-18

Evaxion presents three-year EVX-01 data at ESMO 2026

Evaxion is set to present three-year efficacy data for its AI-designed personalized vaccine EVX-01 at ESMO 2026, offering critical insights into standalone durability in melanoma.NTB Kommunikasjon

Concurrently, researchers demonstrate a reverse vaccinology approach for glioblastoma, screening 446 epitopes from 126 neoantigens to design a multi-epitope construct with strong MHC and TLR-4 binding profiles.PubMed

1new story1 in context

ClinicalyesterdayNew

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 - NTB Kommunikasjon

17.7.2026 13:15:00 CEST | GlobeNewswire by notified | Press release COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present three-year clinica…

news · yesterday · NTB Kommunikasjon

Catching up01

Relevant work from earlier we're still surfacing — not today's news.

Neoantigen-based multi-epitope vaccine designing against glioblastoma using reverse vaccinology and immunoinformatic approaches.europepmc · 5 weeks agoNew

Evaxion presents three-year EVX-01 data at ESMO 2026

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 - NTB Kommunikasjon

Catching up01

Explore the field